Business Description
![Bio-Techne Corp Bio-Techne Corp logo](https://static.gurufocus.com/logos/0C00000CJN.png?14)
Bio-Techne Corp
NAICS : 325414
SIC : 2836
ISIN : US09073M1045
Share Class Description:
FRA:TE1: Ordinary SharesCompare
Compare
Traded in other countries / regions
TECH.USAT1CH34.BrazilTE1.GermanyTECH.Mexico IPO Date
2000-07-10Description
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.36 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 1.34 | |||||
Interest Coverage | 15.44 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 12.4 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.8 | |||||
3-Year EBITDA Growth Rate | 8.1 | |||||
3-Year EPS without NRI Growth Rate | 1.6 | |||||
3-Year FCF Growth Rate | -8.2 | |||||
3-Year Book Growth Rate | 9.2 | |||||
Future 3-5Y EPS without NRI Growth Rate | 16 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.51 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.44 | |||||
9-Day RSI | 36.64 | |||||
14-Day RSI | 39.27 | |||||
6-1 Month Momentum % | 7.63 | |||||
12-1 Month Momentum % | -2.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.87 | |||||
Quick Ratio | 2.75 | |||||
Cash Ratio | 0.96 | |||||
Days Inventory | 168.33 | |||||
Days Sales Outstanding | 69.27 | |||||
Days Payable | 28.53 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.45 | |||||
Dividend Payout Ratio | 0.18 | |||||
Forward Dividend Yield % | 0.45 | |||||
5-Year Yield-on-Cost % | 0.46 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 0.15 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 66.41 | |||||
Operating Margin % | 20.96 | |||||
Net Margin % | 14.5 | |||||
FCF Margin % | 20.35 | |||||
ROE % | 8.4 | |||||
ROA % | 6.2 | |||||
ROIC % | 8.96 | |||||
ROC (Joel Greenblatt) % | 30.68 | |||||
ROCE % | 7.84 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 69.51 | |||||
Forward PE Ratio | 34.35 | |||||
PE Ratio without NRI | 40.61 | |||||
Shiller PE Ratio | 60.73 | |||||
Price-to-Owner-Earnings | 59.99 | |||||
PEG Ratio | 4.95 | |||||
PS Ratio | 10.03 | |||||
PB Ratio | 5.53 | |||||
Price-to-Tangible-Book | 19.42 | |||||
Price-to-Free-Cash-Flow | 49.21 | |||||
Price-to-Operating-Cash-Flow | 38.84 | |||||
EV-to-EBIT | 58.24 | |||||
EV-to-Forward-EBIT | 35.52 | |||||
EV-to-EBITDA | 37.47 | |||||
EV-to-Forward-EBITDA | 29.06 | |||||
EV-to-Revenue | 10.12 | |||||
EV-to-Forward-Revenue | 9.57 | |||||
EV-to-FCF | 49.69 | |||||
Price-to-Projected-FCF | 2.5 | |||||
Price-to-DCF (Earnings Based) | 1.9 | |||||
Price-to-DCF (FCF Based) | 3.21 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 5.33 | |||||
Price-to-Graham-Number | 5.93 | |||||
Earnings Yield (Greenblatt) % | 1.72 | |||||
FCF Yield % | 2.06 | |||||
Forward Rate of Return (Yacktman) % | 9.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bio-Techne Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1,072.98 | ||
EPS (TTM) (€) | 0.963 | ||
Beta | 1.39 | ||
Volatility % | 47.14 | ||
14-Day RSI | 39.27 | ||
14-Day ATR (€) | 1.379988 | ||
20-Day SMA (€) | 68.35 | ||
12-1 Month Momentum % | -2.08 | ||
52-Week Range (€) | 49.4 - 78.5 | ||
Shares Outstanding (Mil) | 158.6 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bio-Techne Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bio-Techne Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Bio-Techne Corp Frequently Asked Questions
What is Bio-Techne Corp(FRA:TE1)'s stock price today?
The current price of FRA:TE1 is €64.50. The 52 week high of FRA:TE1 is €78.50 and 52 week low is €49.40.
When is next earnings date of Bio-Techne Corp(FRA:TE1)?
The next earnings date of Bio-Techne Corp(FRA:TE1) is 2024-10-31 Est..
Does Bio-Techne Corp(FRA:TE1) pay dividends? If so, how much?
The Dividend Yield %  of Bio-Techne Corp(FRA:TE1) is 0.45% (As of Today), Highest Dividend Payout Ratio of Bio-Techne Corp(FRA:TE1) was 0.51. The lowest was 0.16. And the median was 0.28. The  Forward Dividend Yield % of Bio-Techne Corp(FRA:TE1) is 0.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |